asco@alo33:167181 JSONTXT

Background: There is no clear consensus on the management of NM-CRPC outside a clinical trial. Due to lack of clinical trials in NM-CRPC, clinicians are left to choose the best treatment option on the basis of the studies conducted in patients pts ith metastatic CRPC. Methods: We conducted an online survey of 120 Oncologists responsible for the management of prostate cancer PC in the United Kingdom. The survey as designed as a questionnaire on SurveyMonkey ebsite. The Oncologists ere asked to select the management option for a 65 year old man developing NM-CRPC 2 years after radical radiotherapy RT on 1st line, 2nd line and 3rd line setting ith a prostate specific antigen doubling time PSA-DT of lt 6 months, lt 3 months and lt 2 months respectively. They ere then asked to select the factors influencing their treatment decision in this situation including absolute PSA value, PSA-DT, doubling time both or other. Results: 96 of 120 oncologists 80 percent responded. The preferred treatment option for the pt aged 65 ith PSA 18 ngml, PSADT lt 6mo , PSA 38ngml, PSADT lt 3mo , PSA 95ngml, PSA-DT lt 2mo and PSA 95ngml, PSA-DT lt 2mo as active monitoring by 36 percent,29 percent, 41 percent and 57 percent oncologists respectively. For pts ith PSA 38ngml, PSA-DT lt 3mo , both 2nd generation hormone therapy 23 percent and Dexamethasone 23 percent ere considered reasonable approaches. Estrogen as the least preferred option for all patient groups 5 percent,4 percent, 4 percent and 5 percent respectively . Most 49 percent, n = 45 of the Oncologists consider both PSA absolute value and PSA-DT as a decision making factor hile 27 30 percent consider other factors [development of metastases 33 percent n = 9, symptoms 22 percent n = 6, PSADT, absolute PSA value x0026; development of metastases 22 percent n = 6] for treatment of these pts. 18 20 percent Oncologists consider only PSA-DT as a main treatment decision making factor in NM-CRPC patients. Conclusions: In NM-CRPC pts, active monitoring is the most idely preferred choice by oncologists in UK. They consider both absolute PSA value and PSA-DT as important treatment decision making factors. Second generation hormones are preferred than chemotherapy. Results from ongoing clinical trials ill help clinicians decide treatments for this group of pts.,J Clin Oncol 34, 2016 suppl; abstr e16520 ,Publication Only Genitourinary Prostate Cancer